Abeona Therapeutics Reports Second Quarter 2023 Financial Results

On track for Biologics License Application (BLA) submission in third quarter of 2023

Related Keywords

,Nasdaq ,Exchange Commission ,Society For Pediatric Dermatology ,Securities Exchange ,Abeona Therapeutics Inc ,Corporate Communications Abeona Therapeutics ,Drug Administration ,International Societies For Investigative Dermatology ,Biologics License Application ,Vish Seshadri ,Chief Executive Officer ,Process Performance Qualification ,International Societies ,Investigative Dermatology ,Pediatric Dermatology ,Investigational New Drug Application ,Annual Meeting ,American Society ,Cell Therapy ,Entry Code ,Securities Act ,Securities Exchange Act ,Annual Report ,Consolidated Statements ,Seriesb Convertible Redeemable Preferred ,Media Contact ,Greg Gin ,Investor Relations ,Corporate Communications Abeona ,Region ,